The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Open accessAbstract
BACKGROUND: mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients with elevated blood eosinophils (type 2-high), but limited options are available for patients with low blood eosinophils (type 2-low). Inhibiting IL-33 signaling may target pathogenic pathways in a wider spectrum of asthmatics. OBJECTIVES: This study evaluated astegolimab efficacy and safety in patients with severe asthma. METHODS: This double-blind, placebo-controlled, dose-ranging study (ZENYATTA [A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma]) randomized 502 adults with severe asthma to subcutaneous placebo or 70-mg, 210-mg, or 490-mg doses of astegolimab every 4 weeks. The primary endpoint was the annualized asthma exacerbation rate (AER) at week 54. Enrollment caps ensured ∼30 patients who were eosinophil-high (≥300 cells/μL) and ∼95 patients who were eosinophil-low (<300 cells/μL) per arm. RESULTS: Overall, adjusted AER reductions relative to placebo were 43% (P = .005), 22% (P = .18), and 37% (P = .01) for 490-mg, 210-mg, and 70-mg doses of astegolimab, respectively. Adjusted AER reductions for patients who were eosinophil-low were comparable to reductions in the overall population: 54% (P = .002), 14% (P = .48), and 35% (P = .05) for 490-mg, 210-mg, and 70-mg doses of astegolimab. Adverse events were similar in astegolimab- and placebo-treated groups. CONCLUSIONS: Astegolimab reduced AER in a broad population of patients, including those who were eosinophil-low, with inadequately controlled, severe asthma. Astegolimab was safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
A large-scale, consortium-based genomewide association study of asthma
Moffatt, M. F., Gut, I. G., Demenais, F., Strachan, D. P., Bouzigon, E., Heath, S., von Mutius, E., Farrall, M., Lathrop, M., & Cookson, W. O. C. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906312 · Cited by 1,818
Lambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Can Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Mast-Cell Infiltration of Airway Smooth Muscle in Asthma
Brightling, C. E., Bradding, P., Symon, F. A., Holgate, S. T., Wardlaw, A. J., & Pavord, I. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012705 · Cited by 1,241
Self-citationCastro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Interleukin-33 in health and disease
Liew, F. Y., Girard, J.-P., & Turnquist, H. R. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.95 · Cited by 1,147
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Self-citationBousquet, J., Mantzouranis, E., Cruz, A. A., Aït-Khaled, N., Baena-Cagnani, C. E., Bleecker, E. R., Brightling, C. E., Burney, P., Bush, A., Busse, W. W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.07.019 · Cited by 741
Self-citationOrtega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Self-citationCastro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Epithelial cell–derived cytokines: more than just signaling the alarm
Roan, F., Obata-Ninomiya, K., & Ziegler, S. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124606 · Cited by 484
Berry, M., Morgan, A., Shaw, D. E., Parker, D., Green, R., Brightling, C., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2007) · Thorax · doi:10.1136/thx.2006.073429 · Cited by 483
Self-citationA new perspective on concepts of asthma severity and control
Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., de Jongste, J. C., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00155307 · Cited by 472
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00223411 · Cited by 373
Self-citationKearley, J., Silver, J. S., Sanden, C., Liu, Z., Berlin, A. A., White, N., Mori, M., Pham, T.-H., Ward, C. K., Criner, G. J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.011 · Cited by 346
Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity
Kato, A., & Schleimer, R. P. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.08.004 · Cited by 336
Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment
Peters, S. P., Ferguson, G., Deniz, Y., & Reisner, C. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.03.031 · Cited by 320
Agache, I., & Akdis, C. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124611 · Cited by 313
Self-citationEAACI Biologicals Guidelines—Recommendations for severe asthma
Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., et al. (2021) · Allergy · doi:10.1111/all.14425 · Cited by 275
Self-citationIL ‐33: biological properties, functions, and roles in airway disease
Drake, L. Y., & Kita, H. (2017) · Immunological Reviews · doi:10.1111/imr.12552 · Cited by 252
Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study
Shrine, N., Portelli, M. A., John, C., Soler Artigas, M., Bennett, N., Hall, R., Lewis, J., Henry, A. P., Billington, C. K., Ahmad, A., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30389-8 · Cited by 248
Self-citationVannella, K. M., Ramalingam, T. R., Borthwick, L. A., Barron, L., Hart, K. M., Thompson, R. W., Kindrachuk, K. N., Cheever, A. W., White, S., Budelsky, A. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1938 · Cited by 188
Kaur, D., Gomez, E., Doe, C., Berair, R., Woodman, L., Saunders, R., Hollins, F., Rose, F. R., Amrani, Y., May, R., et al. (2015) · Allergy · doi:10.1111/all.12593 · Cited by 166
Self-citationIL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis
Johnston, L. K., Hsu, C.-L., Krier-Burris, R. A., Chhiba, K. D., Chien, K. B., McKenzie, A., Berdnikovs, S., & Bryce, P. J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600611 · Cited by 162
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Casale, T. B., Chipps, B. E., Rosén, K., Trzaskoma, B., Haselkorn, T., Omachi, T. A., Greenberg, S., & Hanania, N. A. (2018) · Allergy · doi:10.1111/all.13302 · Cited by 158
Agache, I. O., Rocha, C. A., Beltran, J., Song, Y., Posso, M., Solà, I., Alonso‐Coello, P., Akdiş, C. A., Akdiş, M., Canonica, G. W., et al. (2020) · Allergy · doi:10.1111/all.14235 · Cited by 146
Self-citationInfection with Influenza Virus Induces IL-33 in Murine Lungs
Goffic, R. L., Arshad, M. I., Rauch, M., L’Helgoualc’h, A., Delmas, B., Piquet‐Pellorce, C., & Samson, M. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0516oc · Cited by 142
A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma
Smith, D. E., Helgason, H., Sulem, P., Björnsdóttir, U. S., Lim, A. C., Sveinbjörnsson, G., Hasegawa, H., Brown, M. E., Ketchem, R. R., Gavala, M. L., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006659 · Cited by 141
Sample Size for Poisson Regression
Signorini, D. F. (1991) · Biometrika · doi:10.1093/biomet/78.2.446 · Cited by 130
Ravanetti, L., Dijkhuis, A., Dekker, T., Piñeros, Y. S. S., Ravi, A., Dierdorp, B., Erjefalt, J. S., Mori, M., Pavlidis, S. P., Adcock, I. M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.051 · Cited by 107
Understanding Interleukin 33 and Its Roles in Eosinophil Development
Johnston, L. K., & Bryce, P. J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00051 · Cited by 105
Differential gene expression and cytokine production from neutrophils in asthma phenotypes
Baines, K. J., Simpson, J. L., Bowden, N. A., Scott, R. J., & Gibson, P. G. (2009) · European Respiratory Journal · doi:10.1183/09031936.00027409 · Cited by 92
An algorithmic approach for the treatment of severe uncontrolled asthma
Ζervas, Ε., Samitas, Κ., Papaioannou, A. Ι., Bakakos, P., Loukides, S., & Gaga, M. (2018) · ERJ Open Research · doi:10.1183/23120541.00125-2017 · Cited by 91
Fuhlbrigge, A. L., Bengtsson, T., Peterson, S., Jauhiainen, A., Eriksson, G., Silva, C. A. D., Johnson, A., Sethi, T., Locantore, N., Tal‐Singer, R., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30218-7 · Cited by 51
Current application of exhaled nitric oxide in clinical practice
Spahn, J. D., Malka, J., & Szefler, S. J. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.002 · Cited by 48
Interleukin‐33 in the developing lung—Roles in asthma and infection
Johansson, K., & McSorley, H. J. (2019) · Pediatric Allergy and Immunology · doi:10.1111/pai.13040 · Cited by 40
Beyond type 2 cytokines in asthma - new insights from old clinical trials
Choy, D. F., & Arron, J. R. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1744567 · Cited by 13
Self-citation
Cited by
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Type 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Cayrol, C., & Girard, J.-P. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155891 · Cited by 322
Biologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Helminth Therapy for Immune-Mediated Inflammatory Diseases: Current and Future Perspectives
Shi, W., Xu, N., Wang, X., Vallée, I., Liu, M., & Liu, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s348079 · Cited by 46
Metadata
- Authors
- Kelsen, S. G., Agache, I. O., Soong, W., Israel, E., Chupp, G. L., Cheung, D. S., Theess, W., Yang, X., Staton, T. L., Choy, D. F., Fong, A., Dash, A., Dolton, M., Pappu, R., & Brightling, C. E.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 148
- Issue
- 3
- Pages
- 790-798
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3152867209
- Cited by
- 319
- References
- 42
- FWCI
- 24.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.